

The PHOENIX RCT

Planned delivery for pre-eclampsia between 34 and 37 weeks of gestation: the PHOENIX RCT

Lucy C Chappell,^{1*} Peter Brocklehurst,²
Marcus Green,³ Pollyanna Hardy,⁴ Rachael Hunter,⁵
Alice Beardmore-Gray,¹ Ursula Bowler,⁴
Anna Brockbank,¹ Virginia Chiocchia,⁴ Alice Cox,¹
Kate Duhig,¹ Jessica Fleminger,¹ Carolyn Gill,⁶
Melanie Greenland,⁴ Eleanor Hendy,¹ Ann Kennedy,⁴
Paul Leeson,⁷ Louise Linsell,⁴ Fergus P McCarthy,⁸
Jamie O'Driscoll,⁹ Anna Placzek,⁴ Lucilla Poston,¹
Stephen Robson,¹⁰ Pauline Rushby,⁴ Jane Sandall,¹
Laura Scholtz,¹ Paul T Seed,¹ Jenie Sparkes,¹
Kayleigh Stanbury,⁴ Sue Tohill,⁶ Basky Thilaganathan,¹¹
John Townend,¹² Edmund Juszczak,¹³ Neil Marlow¹⁴ and
Andrew Shennan¹ on behalf of the PHOENIX Study Group

¹School of Life Course Sciences, King's College London, London, UK

²Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK

³Action on Pre-eclampsia, Evesham, UK

⁴National Perinatal Epidemiology Unit Clinical Trials Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK

⁵Research Department of Primary Care and Population Health, University College London, London, UK

⁶Guy's and St Thomas' NHS Foundation Trust, London, UK

⁷Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK

⁸Department of Obstetrics and Gynaecology, University of Cork, Cork, Ireland

⁹School of Psychology and Life Sciences, Canterbury Christ Church University, Kent, UK

¹⁰Population Health Institute, Newcastle University, Newcastle upon Tyne, UK

¹¹Fetal Medicine Unit, St George's University Hospitals NHS Foundation Trust, London, UK

¹²Frontier Science (Scotland) Ltd, Kincaig, UK

¹³Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK

¹⁴Institute for Women's Health, University College London, London, UK

*Corresponding author lucy.chappell@kcl.ac.uk

Disclosure of interests of authors

Full disclosure of interests: Completed ICMJE forms for all authors, including all related interests, are available in the toolkit on the NIHR Journals Library report publication page at <https://doi.org/10.3310/CWWH0622>.

Primary conflicts of interest: Lucy C Chappell was chairperson of the National Institute for Health and Care Research (NIHR) Health Technology Assessment (HTA) Clinical Evaluation and Trials (CET) committee (2019–21) and is NIHR Chief Executive Officer (2021 to present). Pollyanna Hardy reports membership of the NIHR HTA Commissioning Board. Paul Leeson reports membership of the NIHR Invention for Innovation (i4i) Committee B and NIHR Fellowship Committee. Basky Thilaganathan reports honoraria for Key Opinion Leader (KOL) online lectures from Koninklijke Philips N.V. (Amsterdam, the Netherlands) and payments for sessional times. Edmund Juszcak reports membership of the NIHR HTA General Board (2013–16). Neil Marlow reports consulting fees from InfanDx AG (Cologne, Germany) and lecture fees from Chiesi UK (Manchester, UK). Andrew Shennan reports membership of the NIHR HTA Commissioning Board and is chairperson of the Action on Pre-eclampsia.

Published December 2023

DOI: 10.3310/XGHP2049

Plain language summary

Planned delivery for pre-eclampsia between 34 and 37 weeks of gestation: the PHOENIX RCT

Health Technology Assessment 2023; Vol. 27: No. 28

DOI: 10.3310/XGHP2049

NIHR Journals Library www.journalslibrary.nihr.ac.uk

Plain language summary

Why did we do this trial?

We know that pre-eclampsia is a common condition and can cause serious illness in a pregnant woman or baby. It is unclear how we should best advise women about the timing of delivery if they develop the condition between 34 and 37 weeks of pregnancy. We wanted to compare planned early birth and usual clinical practice (that is, planning birth at 37 weeks of pregnancy, or sooner if needed for clinical reasons).

What did we do?

Between September 2014 and December 2018, 901 women with pre-eclampsia between 34 and 37 weeks of pregnancy agreed to take part. Half of the women were randomised to planning the birth of their babies within 48 hours and half were randomised to watching and waiting. During the study we collected pregnancy and birth information and health outcomes for the mother and the baby for 2 years after birth.

What did we find?

We found that planned early birth is better for these women, with fewer complications such as severely high blood pressure. We found that more babies in the planned birth group were admitted to the neonatal unit, mainly because they were premature, but they did not have more complications such as breathing problems and they did not stay longer in the unit than babies in the usual clinical practice group. At 2 years old, the babies in both groups had similar scores for development, with their average scores in the normal range.

What does this mean for women with pre-eclampsia?

Women with pre-eclampsia and their doctors will be able to make better decisions about the timing of delivery. Because the number of complications was reduced, and there was no difference in complications for the baby (though more babies were admitted to the neonatal unit), women and their doctors may use this information to share decision-making around timing of delivery.

Health Technology Assessment

ISSN 1366-5278 (Print)

ISSN 2046-4924 (Online)

A list of Journals Library editors can be found on the [NIHR Journals Library website](#)

Impact factor: 3.6

Launched in 1997, *Health Technology Assessment* (HTA) has an impact factor of 3.6 and is ranked 32nd (out of 105 titles) in the 'Health Care Sciences & Services' category of the Clarivate 2021 Journal Citation Reports (Science Edition). It is also indexed by MEDLINE, CINAHL (EBSCO Information Services, Ipswich, MA, USA), Embase (Elsevier, Amsterdam, the Netherlands), NCBI Bookshelf, DOAJ, Europe PMC, the Cochrane Library (John Wiley & Sons, Inc., Hoboken, NJ, USA), INAHTA, the British Nursing Index (ProQuest LLC, Ann Arbor, MI, USA), Ulrichsweb™ (ProQuest LLC, Ann Arbor, MI, USA) and the Science Citation Index Expanded™ (Clarivate™, Philadelphia, PA, USA).

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).

Editorial contact: journals.library@nhr.ac.uk

The full HTA archive is freely available to view online at www.journalslibrary.nhr.ac.uk/hta.

Criteria for inclusion in the *Health Technology Assessment* journal

Reports are published in *Health Technology Assessment* (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in *Health Technology Assessment* are termed 'systematic' when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA programme

Health Technology Assessment (HTA) research is undertaken where some evidence already exists to show that a technology can be effective and this needs to be compared to the current standard intervention to see which works best. Research can evaluate any intervention used in the treatment, prevention or diagnosis of disease, provided the study outcomes lead to findings that have the potential to be of direct benefit to NHS patients. Technologies in this context mean any method used to promote health; prevent and treat disease; and improve rehabilitation or long-term care. They are not confined to new drugs and include any intervention used in the treatment, prevention or diagnosis of disease.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

Copyright © 2023 Chappell *et al.* This work was produced by Chappell *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. See: <https://creativecommons.org/licenses/by/4.0/>. For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.

Published by the NIHR Journals Library (www.journalslibrary.nhr.ac.uk), produced by Newgen Digitalworks Pvt Ltd, Chennai, India (www.newgen.co).